2 results
Approved WMORecruiting
Phase 2:Primary ObjectivesTo determine the recommended Phase3 dose of mitapivat by evaluating the effect of 2 dose levels of mitapivat versus placebo on:• Anemia in subjects with sickle cell disease (SCD)• SafetySecondary ObjectivesTo evaluate the…
Approved WMORecruiting
Objective: The primary aim of the study is to demonstrate that cervical administered ITB is a safe treatment of spasticity of the UE without deterioration of pulmonary function, respiration and sleep-related breathing disorders.